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Summary ACNU [1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride],
one of the chloroethylnitrosoureas (CENUs), is believed to be effective against malignant glioma when
intravenously or intrathecally administered. A rat model with meningeal gliomatosis (MG) induced by an
intracisternal inoculation of rat C6 or 9L glioma cells was intrathecally and intravenously treated with ACNU
in order to test the feasibility of intrathecal chemotherapy with ACNU in the treatment of meningeal
gliomatosis. The median survival time (MST) of the animals was significantly prolonged when ACNU was
intrathecally administered at dosages of 0.5 to 1.5 mg kg-' in the early stages of MG, i.e. within 3 days after
the tumour inoculation, whereas intravenous therapy with ACNU at a dose of 15 mg kg- ' did not exhibit any
efficacy in the rats inoculated with C6 glioma cells (C6-MG). Intrathecal ACNU, however, at dosages of up to
1.5 mg kg-' failed to demonstrate any therapeutic effect in the late stage of MG, i.e. 5 days after the tumour
inoculation, except in the rats inoculated with 9L brain tumour cells (9L-MG). Intravenous chemotherapy
with ACNU at a dose of 15 mg kg-' extended the MST of the 9L-MG rats more significantly in the late stage
of MG than in its early stage. This points to the feasibility of intrathecal ACNU in the treatment ofmeningeal
gliomatosis in its early stages, but not in its late stages in which intravenous ACNU might be more effective
than intrathecal treatment against MG of which the parenchyma has already been deeply invaded by the
tumour.
Meningeal gliomatosis (MG), characterised either by its
pathologically multifocal nature or its diffuse infiltration of
glioma cells into the subarachnoid space, is a serious com-
plication of malignant glioma and has been thought to be
comparatively rare (Yung et al., 1980). However, it has been
disclosed that the incidence of MG is 10-20% of patients
with malignant brain tumours, and recent reports have
claimed its increase along with the prolongation of life span
of patients with malignant glioma (Arita et al., 1984; Yosh-
ida et al., 1986a,c). Furthermore, the prognosis of these
patients has not been significantly modified to date.
Systemic chemotherapy cannot achieve an effective drug
concentration in cerebrospinal fluid (CSF) to overcome the
drug resistance acquired during the initial chemotherapy for
the primary tumour (Levin et al., 1985, 1989; Yoshida et al.,
1984b, 1985, 1986b, 1987a). Thus, the treatment of MG is
limited to radiation therapy of the brain and the spinal cord
and/or the use of a limited number of antitumour drugs
which can be administered directly into the spinal subarach-
noid space (intrathecally) or cerebral ventricles (Bleyer, 1978;
Hitchins et al., 1987). Although radiotherapy is sometimes
effective, as in CNS leukaemia prophylaxis, it has toxic
effects on the brain that result in intellectual impairment even
at low doses (Hutsu et al., 1973). Drugs such as methotrexate
(Blasberg et al., 1977; Schulier et al., 1985; Shapiro et al.,
1977), 1-P-D-arabinofuranosylcytosine (Edwards et al., 1981;
Fulton et al., 1982), thio-TEPA (Gutin et al., 1976, 1977),
bleomycin (Levin et al., 1985; Ushio et al., 1987), and
neocarzinostatin (Matsukado et al., 1980; Yoshida et al.,
1987b) intrathecally administered have demonstrated some
therapeutic effect, however, the results are not sufficient
(Ushio et al., 1987).
One of the chloroethylnitrosoureas (CENUs), ACNU [1-
(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-
nitrosourea hydrochloride] (Nakamura et al., 1977), has been
used via intravenous administration and has demonstrated
remarkable efficacy as the other CENUs against brain tu-
mours diffusely invading into the parenchyma (Takakura et
al., 1986). However, the systemic administration of this drug
is not always effective on MG (Ushio et al., 1987; Yoshida et
al., 1984a). ACNU has the following pharmacological char-
acteristics: it crosses the blood-brain barrier (B.B.B.) (Ushio
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et al., 1981), its half-life is short in the blood and the
cerebrospinal fluid (CSF), and its capillary transfer constant
is high (Levin et al., 1985). Accordingly, these characteristics
are considered to be favourable for intrathecal chemotherapy
with respect to the side effects of the chemotherapeutic agents
(Ohashi, 1987). In order to study the feasibility of intrathecal
chemotherapy with ACNU in the treatment of MG, experi-
mental models have been intrathecally treated with ACNU
according to its pathophysical stages. In this communication,
a remarkable efficacy of intrathecal treatment with ACNU in
rat MG models was demonstrated, and, in addition, several
pathophysiological problems associated with the treatment of
MG are discussed.
Materials and methods
Tumours and animals
Male Wistar and Fischer 344 rats, each weighing approx-
imately 100 gm, were used in the experiments. Wistar rats
were the carrier of C6 glioma (Benda et al., 1968), and
Fischer 344 rats bore 9L brain tumour (Barker et al., 1973).
C6 and 9L glioma are well established cell lines, which were
cultured in Eagle's MEM supplemented with 10% heat-
inactivated foetal bovine serum (Grand Island Biological Co.,
Grand Island, NY), a penicillin base (50 units ml-'), and a
streptomycin base (50fig ml-') (both from Grand Island
Biological Co.) at 37°C in a humidified atmosphere supplied
with 5% CO2.
Drug
ACNU, formulated for clinical use, was obtained from San-
kyo Pharmaceutical Co. (Tokyo, Japan).
Toxicity
The systemic toxicity of intrathecally administered ACNU
was studied in rats after injections of 0.5, 1.0, 1.5, or
3 mg kg-' of ACNU, dissolved in 0.1 ml of distilled water,
into the cisterna magna (ten rats in each group). Neuro-
logical symptoms, behavioral changes, body weight changes
and survival time were observed and recorded. In another
group of rats, local neurotoxicity in the brain was studied.
The rats given intracisternal ACNU at the same doses as
described above (two rats in each group) were sacrificed
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30 min after intravenous Evans blue administration (1 ml of
0.5% solution), 1, 5, 10, 20 and 30 days after intracisternal
ACNU administration. The brain was removed and then the
leakage of Evans blue in the brain tissue was studied. The
histopathological studies were also performed. The control
rats were administered with equal volumes of the drug-free
diluent.
Meningeal gliomatosis (MG) models
Details regarding the present models have been described
previously (Yoshida et al., 1986a,c). Using a 27 gauge needle,
0.1 ml of cell suspensions of 1 x 107 C6 or 9L glioma cells
were transplanted percutaneously under ether anesthesia into
the cisterna magna of Wistar or Fischer 344 rats, respec-
tively; these are referred to here as 'meningeal gliomatosis
(MG) rats, i.e. C6 and 9L MG rats, respectively'.
Intrathecal and intravenous chemotherapy ofa meningeal
gliomatosis (MG) model with ACNU
Each group of 10 MG rats was treated with ACNU intra-
thecally at dosages of 0.5, 1.0 and 1.5 mk kg' or intra-
venously at a dosage of 15 mg kg-' with a volume of 0.1 ml
100 gm-' body weight, respectively, on Day 1, 3 or 5 after
tumour inoculation. Control group was treated with equal
volumes of the drug-free diluent. The life spans of the treated
and control MG rats were compared and analysed by a
modified Wilcoxon rank sum analysis. The dosages of in-
trathecal or intravenous ACNU were determined by the tox-
icity examinations in our previous studies (Arita et al., 1988;
Yoshida et al., 1984a,b,c, 1987c). Antitumour activity was
expressed as follows: the mean survival time of the ACNU-
treated group divided by the mean survival time of the
control group (T/C).
In vitro sensitivity assay
A colony-forming assay (Deen et al., 1979) was used to
determine the cell survival. Briefly, single cell suspensions
with an exponentially growing phase were exposed to various
concentrations ofACNU for 2 h, and 300 to 1000 viable cells
were plated on 60 mm tissue culture dishes (Falcon Plastics,
Oxnard, Calif.) containing the same culture medium as
above. Cultures were incubated at 37°C in a humidified
chamber with 5% CO2 for 2 weeks at which time the medium
was discarded and the colonies were fixed with 95% meth-
anol, stained with methylene blue, and counted. Colonies of
50 cells or more were counted, and survival fractions were
estimated in triplicate dishes and calculated as follows:
[(Mean no. of colonies in treated dishes) divide by (Mean
no. of colonies in control dishes)] x 100
Pathological examination
MG rats without treatment were sacrificed for histological
examination on Day 5. The intact skull and vertebral column
were freed from overlying soft tissue, fixed in 10% formalin,
then decalcified. The brains were cut coronally and embedded
in parafin. Coronal sections of the brain of 5 ji in thickness
were processed for the hematoxylin-eosin (HE) and
immunoperoxidase method using antiserum to glial fibrillary
acidic protein (GFAP) (Bignami et al., 1972). This immuno
histological method has been described (Yoshimine et al.,
1982). Briefly, the indirect peroxidase-labelled method was
carried out at room temperature. Sections were incubated for
40 mmn with rabbit anti-GFAP antiserum diluted 10-fold with
0.05 M phosphate buffered saline (PBS, pH 7.2), washed in
PBS, reacted for 40 min with peroxidase-labelled goat anti-
rabbit IgG antiserum (containing 0.4 mg of protein, JIMRO,
Japan), washed in PBS, incubated for 5 to 15 min in 0.05 M
tris buffer (pH 7.6) containing 0.005% hydrogen peroxide
and 0.03% 3,3'-diamino-benzidine tetrahydrochloride, wash-
ed, dehydrated, cleaned in xylol, and mounted on glass slides.
Results
Toxicity ofintrathecal ACNU
Body weight changes in each group of rats and the number
of rats which died of acute toxicity of ACNU after an
intrathecal administration of ACNU are demonstrated in
Figure 1. In the control groups and the groups of rats which
received 0.5, 1.0 or 1.5 mg kg-1 of intrathecal ACU treat-
ment, the body weight of the rats constantly increased and
neither loss of appetite, behavioural changes nor neurological
signs were observed during or after intrathecal administra-
tion. On the other hand, in the group treated with 3.0
mgkg-1 ACNU, the body weight of the rats rapidly de-
creased to approximately 70% of baseline, and 60% of the
rats died of acute toxicity of ACNU showing acute appetite
loss, and various kinds of neurological signs or behavioural
changes such as a decrease in activity, nervous reactions, a
tendency toward violence, hemiparesis, muscular spasms and
respiratory disorders.
In the rats given over 3.0 mg kg-' of intrathecal ACNU,
the subpial regions of the ambient cistern, the base of the
brain and the hippocampal fissue were stained with Evans
blue 5 days after injection. Pathologically, neuronal loss and
gliosis were also noted in the same regions as above. These
changes were observed thereafter up to 30 days after injec-
tion. In the rats intrathecally administered with ACNU at
dosages less than 1.5 mg kg-', neither the extravasation of
Evans blue nor pathological changes such as those mentioned
above were observed up to 30 days after injection.
Effect ofintrathecal ACNU in MG rats
Table I demonstrates the results of intrathecal chemotherapy
with ACNU in MG rats at dosages of 0.5, 1.0, or 1.5 mg
kg-'. When intrathecally administered 1 day or 3 days after
tumour inoculation, ACNU markedly prolonged the survival
time of MG rats (Figures 2 and 3a,b). When the animals
were treated with 1.5 mg kg-1 of ACNU on Day 1, the T/C
value was 163.4% and 265.0% for C6 MG and 9L MG rats,
respectively, and on Day 3, it was 140.9% and 190.1% for
C6 MG and 9L MG rats, respectively. Intrathecal ACNU
administered 5 days after tumour inoculation failed to pre-
vent tumour growth in C6 MG rats, but not in 9L MG rats
in which the median survival time (MST) was still prolonged
by the treatment with 1.0 or 1.5 mg kg-' ACNU, and the
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Figure 1 Changes of the body weight of the rats after a single
intrathecal administration of ACNU on Day 0 at the indicated
dosages. n = the number of rats in each group.ACNU FOR MENINGEAL GLIOMATOSIS 1001
Table I The effect of intrathecal ACNU on C6 MG rats (A),
inoculated with C6 glioma cells, and 9L MG rats (B), inoculated
with 9L glioma cells
Dose of Median
ACNU Day of survival TIC
(mg/kg) treatment time (day) (%)
A C6-MG rats
Control 14.0
0.5 1 19.0 132.4a
3 17.0 120.0
5 14.0 99.3
1.0 1 19.5 142.9b
3 18.0 128.6a
5 15.5 107.1
1.5 1 22.5 163.4b
3 20.0 140.9b
5 16.0 112.2
B 9L-MG rats
Control 14.5
0.5 1 21.5 154.3b
3 20.0 140.lb
5 17.5 121.0
1.0 1 31.0 212.0b
3 25.0 172.6b
5 18.5 125.0
1.5 1 38.0 265.0b
3 27.5 190.1b
5 19.5 135.Oa
Each group of rats were treated with intravenous ACNU at a
dosage of 0.5, 1.0 or 1.5mgkg-', 1, 3 or 5 days after inoculation.
T/C = mean survival time of treated rats/mean survival time of
control rats; s.d. = standard deviation. aStatistically significant
(P<0.05) by a modified Wilcoxon rank sum analysis as compared
with that of the control group. bStatistically significant (P<0.01) by
amodified Wilcoxon ranksum analysis as compared with that of the
control group.
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Figure 2 Survival curves (Kaplan-Meier) of C6 MG rats, inocu-
lated with 1 x 107 C6 glioma cells, treated once intrathecally (it)
with ACNU at a dosage of 0.5, 1.0 or 1.5 mg kg-', I (a), 3 (b) or
5 (c) days after inoculation. n = the number of rats in each
group.
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Figure 3 Survival curves (Kaplan-Meier) of 9L MG rats, inocu-
lated with 1 x 10' 9L glioma cells, treated once intrathecally (it)
with ACNU at a dosage of 0.5, 1.0 or 1.5 mg kg- , 1 (a), 3 (b) or
5 (c) days after inoculation. n = the number of rats in each
group.
T/C value was 125.0% and 135.0%, respectively (Figures 2
and 3c, Table I).
Table II demonstrates the results after intravenous treat-
ment of MG rats with ACNU at a dosage of 15 mg kg-'. In
C6 MG rats, no chemotherapeutic effect was observed in any
of the regimens, while the MST of 9L MG rats was
significantly prolonged by an intravenous administration of
ACNU. When treated 1, 3, or 5 days after tumour inocula-
tion, intravenous ACNU prolonged the survival time of 9L
MG rats, by the T/C values, 157.0%, 171.0% and 187.0%,
respectively. Intrathecal treatment with a one-tenth dose of
ACNU displayed more efficacy than did intravenous treat-
ment 1 day after tumour inoculation, whereas the latter was
more effective than the former 5 days after tumour inocula-
tion.
Drug sensitivity ofC6 and 9L cells in vitro
The dose response curves for C6 and 9L cells are shown in
Figure 4. C6 cells were more resistant to ACNU than were
9L cells in vitro.
Pathologicalfindings
The pathological changes in the rats intracisternally inocu-
lated with C6 glioma cells 5 days after tumour inoculation
are shown in Figure 5. The immunoperoxidase method dem-
onstrated an intense astrocytic reaction in the vicinity of the
tumour invasion. The reaction was manifested as the pro-
liferation of hypertrophied astrocytes, which developed fibril-
lated processes. Furthermore, a direct tumour invasion by
destroying the ependymal cell barrier was observed in the
lateral, third and fourth ventricles at this stage. The epen-
dymal cells reacted strongly with the GFAP antiserum.
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Table II The effect of intravenous ACNU on C6 MG (A) and 9L
MG (B) rats
Dose of Median
ACNU Day of survival TIC
(mg/kg-') treatment time (day) (%)
A C6-MG rats
Control 14.0
15.0 1 15.5 112.6
3 15.0 106.3
5 14.0 97.1
B 9L-MG rats
Control 14.5
15.0 1 22.5 157.Oa
3 24.0 171.Oa
5 27.5 187.Oa
Each group of rats were treated with intrathecal ACNU at a
dosage of 15 mg kg-', 1, 3 or 5 days after tumour inoculation.
T/C = mean survival time of treated rats/mean survival time of
control rats; s.d. = standard deviation. aStatistically significant (P,
0.01) by a modified Wilcoxon ranksum analysis as compared with
that of the control group.
Discussion
The treatment of meningeal gliomatosis (MG) is limited to
irradiation to the brain and the spinal cord or to the use of a
limited number of drugs that can be intrathecally or intra-
ventricullarly administered (Levin et al., 1989). These conven-
tional treatments have failed to lead to satisfactory results in
treating patients with MG. It has been reported that the
incidence of this disorder is relatively high and that it is
increasing along with recent progress in the treatment of
brain tumours (Arita et al., 1988; Ushio et al., 1987; Yoshida
et al., 1986a,c, 1987c). Due to the limited information
available concerning the pathophysiology of this disease, no
consistent method of treatment has yet been introduced.
Therefore, it is necessary to design a more effective therapy
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Figure 4 Survival fractions of C6 (0 O) and 9L (0 0)
glioma cells after treatment of with ACNU for 2 h. Each point is
the mean of three determinations. The vertical bars indicate
standard deviations (s.d.).
for this disease. While examining the alternative methods of
treatment for MG, we have observed the efficacy of the
intrathecal administration of ACNU in rat animal models
(Yoshida et al., 1984b). Although the feasibility of this
therapy has been extensively studied (Arita et al., 1988;
Nagatani et al., 1986; Kochi et al., 1990; Levin et al., 1989;
Yoshida et al., 1987c), further studies with regard to the
pathophysiology of MG and the drug sensitivity of the
tumour cells are required in order to investigate the most
appropriate regimen of this new therapy.
Figure 5 Section of the brain adjacent to the right lateral ventricle of a MG rat sacrificed 5 days after inoculation of C6 glioma
cells. Direct tumour invasion into the parenchyma by destroying the ependymal cells is noted. The reactive ependymal cells and
astrocytes with thickened process are demonstrated with anti-GFAP antibody. Immunoperoxidase, x 108.ACNU FOR MENINGEAL GLIOMATOSIS 1003
Pharmacokinetics andpharmacodynamics ofACNU in vivo
According to the results of a toxicity test, a dose of up to
1.5 mg kg-' of ACNU was proven t9 be safely administered
intrathecally. The antitumour activity of intrathecal ACNU
at dosages of 0.5, 1.0 and 1.5 mgkg-' was examined in MG
models. It was shown that the median survival time of MG
rats was statistically prolonged with low dosages of the drug
(0.5 or 1 mg kg-') in the early stages of MG (1 or 3 days
after tumour inoculation), however a comparatively high
dose of ACNU (1.5 mg kg-') failed to demonstrate its satis-
factory efficacy in the late stages of MG (later than 5 days
after tumour inoculation). By contrast, intravenous therapy
with 15 mg kg-' of ACNU displayed more efficacy in the late
stages of 9L MG rats than did intrathecal therapy although
no chemotherapeutic effects was seen in C6 MG rats.
According to Rosenblum et al. (Rosenblum et al., 1983),
the maximum clinically achievable dose of the chemothera-
peutic agents at the tumour cell in situ was estimated to be
8.5 JLM when a single intravenous dose of BCNU was admin-
istered at a clinical dose of 180 to 220 mg sq m-. Further-
more, they reported that the cell kill value of 40% in vitro
can be logically adopted to estimate a clinical response to
chemotherapy in vivo. In the present study, 40% cell kill
value in vitro required 2.3 JAM of ACNU for 9L cells and
21.4JLM for C6 glioma cells, respectively. This explains the
results of the present experiments in which intravenous
ACNU did not demonstrate any therapeutic effect in C6 MG
rats, while it did in 9L MG rat models. This suggests that the
achievable dose of ACNU in vivo by intravenous administra-
tion is insufficient in some tumour cells originally resistant to
ACNU, such as C6 glioma cells, in attaining the cell kill to
bring about a clinical response. On the other hand, high CSF
concentrations and the AUC (area under the drug concen-
tration-time curve) values were obtained when ACNU was
perfused through the intraventricular administration in the
dogs (Kochi et al., 1990), and intraventricular or intrathecal
bolus administration of BCNU also achieved the high values
of the maximum concentration and AUC in human trials
(Levin et al., 1989). Although these data can support the
results of the remarkable therapeutic effect of intrathecal
therapy for both C6 and 9L MG models in the early stages
of MG, the diminished effect of intrathecal ACNU therapy
in the late stages cannot be explained.
Pathophysiology ofMG andblood-brain barrier (B.B.B.)
In order to clarify the above mentioned phenomenon, the
pathophysiology must be understood. According to our
previous study on MG (Yoshida et al., 1986a,c), tumour cells
inoculated into the subarachnoid space remained to be
floating cells in the CSF with forming spheroids a few days
after tumour inoculation. On the third day, the tumour
began to invade the parenchyma through the perivascular
space of the penetrating vessels, which was followed by the
complete invasion into the parenchyma by the 5th day after
tumour inoculation (Figure 5). This might be one of the
reasons for the reduced effect of ACNU accompanied by the
progress of MG. Thus, once tumour cells start to invade into
the parenchyma, it might become difficult to prevent tumour
growth by intrathecal chemotherapy alone. Furthermore, the
tumour nodules, along with the parenchymal invasion, were
also observed in the late stages of MG rats. It has been
demonstrated that the penetration of drugs into the tumour
nodules greater than 5Smm was severely compromised in
nodules of the peritoneal space tumour implants (Flessner et
al., 1984, 1985).
In the late stages of 9L MG rats, intravenous treatment
conversely demonstrated a therapeutic effect, whereas intra-
thecal ACNU almost failed to show its efficacy. It is
therefore conceivable that the drug concentration achievable
by intravenous administration was not high enough to kill
the floating cells up to a 40% cell kill value in the subarach-
noid space in the early stages of MG. However, in the late
stages, the concentration of ACNU seemed to be sufficient to
kill those cells which had deeply invaded into the paren-
chyma (Figure 5). This was also demonstrated by Ushio et al.
(Ushio et al., 1981) in a meningeal carcinomatosis model.
They claimed that the blood-CSF barrier or blood-brain
barrier (B.B.B.) alters along with the pathophysiological
changes of the meningeal tumour, which facilitates the drugs
crossing the B.B.B. (Ushio et al., 1981). This is supported by
the other investigators who demonstrated that the alteration
of the B.B.B. in the ethylnitrosourea-induced rat glioma
depends on the sizes of the tumours induced (Yamada et al.,
1981). The late effect of intravenous administration in this
study is likely to be related with this phenomenon, i.e. the
alteration of the B.B.B. or the blood-CSF barrier.
Problems in the treatment ofMG
One of the problems in the treatment of MG is how to
overcome the drug resistance acquired resistance during the
initial chemotherapy for the primary tumour (Yoshida et al.,
1984b; 1986b,d; 1987a,b; Yoshida et al., 1987d). Although
CENUs are comparatively effective against glioma (Ushio et
al., 1987), the required drug concentration is relatively high
in order to attain the effective cell kill in most of the clinical
cases (Rosenblum et al., 1983). For instance, using the data
from Figure 4, 1-log cell kill values for C6 and 9L cells
become 91.0 and 9.6 liM, respectively. This means that C6
cells are originally ten times more resistant to ACNU than
are 9L cells, which is the responsible factor for the failure of
intravenous therapy for C6 MG rats.
The other problem is how to treat patients with MG in its
late stages. In spite of a remarkable therapeutic effect of a
low dose of intrathecal ACNU in the early stages of MG, its
efficacy decreased in the late stages of MG as the patho-
physiology acutely altered in a short time. In these stages,
tumour cells have already deeply invaded the parenchyma, to
which ACNU cannot easily reach by an intrathecal adminis-
tration. Indeed, Arita et al. demonstrated that intracisternally
administered ACNU quickly spread in the subarachnoid
space and subpial layer of the brain and that the drug could
not penetrate into the parenchyma (Arita et al., 1988).
Therefore, it is stressed that the treatment of MG should be
carried out depending on its pathophysiological and clinical
stages, which was partly reported in our previous com-
munications (Yoshida et al., 1986a,c; 1987c). The additional
treatments, including combination chemotherapy (Yoshida et
al., 1984a; 1987a), are necessary for the advanced stages of
MG. Further studies are under way to gain better understan-
ding of these particular problems in the treatment of MG.
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